Literature DB >> 30591516

AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?

Scott M Dehm1, Bruce Montgomery2,3, Stephen R Plymate4,3.   

Abstract

Circulating tumor cells' (CTC) biomarkers may become indicators for selection of therapy. The presence of androgen receptor (AR)-variant-positive CTCs may be markers indicating the need for switching therapy. Methods for AR-variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable.See related article by Tagawa et al., p. 1880. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 30591516     DOI： 10.1158/1078-0432.CCR-18-3727

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  4 in total

Review 1.  Targeting the androgen receptor and overcoming resistance in prostate cancer.

Authors:  David J Einstein; Seiji Arai; Steven P Balk
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

2.  High-Throughput Automated Microscopy of Circulating Tumor Cells.

Authors:  Carlos Aguilar-Avelar; Brenda Soto-García; Diana Aráiz-Hernández; Juan F Yee-de León; Miguel Esparza; Franco Chacón; Jesús Rolando Delgado-Balderas; Mario M Alvarez; Grissel Trujillo-de Santiago; Lauro S Gómez-Guerra; Liza P Velarde-Calvillo; Alejandro Abarca-Blanco; J D Wong-Campos
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

3.  Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells.

Authors:  Manuel Abreu; Pablo Cabezas-Sainz; Thais Pereira-Veiga; Catalina Falo; Alicia Abalo; Idoia Morilla; Teresa Curiel; Juan Cueva; Carmela Rodríguez; Vanesa Varela-Pose; Ramón Lago-Lestón; Patricia Mondelo; Patricia Palacios; Gema Moreno-Bueno; Amparo Cano; Tomás García-Caballero; Miquel Ángel Pujana; Laura Sánchez-Piñón; Clotilde Costa; Rafael López; Laura Muinelo-Romay
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

4.  Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.

Authors:  Francesca Galardi; Francesca De Luca; Chiara Biagioni; Ilenia Migliaccio; Giuseppe Curigliano; Alessandro M Minisini; Martina Bonechi; Erica Moretti; Emanuela Risi; Amelia McCartney; Matteo Benelli; Dario Romagnoli; Silvia Cappadona; Stefano Gabellini; Cristina Guarducci; Valerio Conti; Laura Biganzoli; Angelo Di Leo; Luca Malorni
Journal:  Breast Cancer Res       Date:  2021-03-24       Impact factor: 6.466
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.